Table 2.
The effect of genotypes and clinical covariates on tacrolimus clearance (Cl/F) and final parameters estimates
| Parameter/Covariate | Model development cohort. Estimate (%RSEa) of the effect on TVCl/F | Bootstrap analysis. Median (95% confidence interval) |
|---|---|---|
| Typical Value of Cl/F (TVCl/F) in L/hr | 54.60 (10.0%) | 54.48 (44.51–66.63) |
| Two loss of function alleles (CYP3A5*3/*3 or *3/*7 or CYP3A5*3/*6 or *6/*7) | 0.53 (10.9%) | 0.53 (0.43–0.66) |
| One loss of function alleles (CYP3A5*1/*3 or CYP3A5*1/*6 or CYP3A5*1/*7) | 0.85 (9.7%) | 0.85 (0.70–1.04) |
| Less than day 9 posttransplant | 1.33 (4.2%) | 1.33 (1.23–1.45) |
| Steroid drug use | 1.23 (6.9%) | 1.24 (1.07–1.42) |
| Antiviral drug use | 0.92 (2.9%) | 0.91 (0.87–0.97) |
| Recipient age (18–34 yrs) | 1.24 (7.8%) | 1.24 (1.07–1.47) |
| Between subject variabilityb | 0.21 (18.1%) [CV%=48.6%] |
0.21 (0.14–0.28) [CV%= 46.7% (38.76–56.84%] |
| Residual unexplained variability in trough (ng/mL) | 2.76 (7.5%) | 2.75 (2.55–2.96) ng/mL |
a
RSE is relative standard error
b
0.21 represents the estimate of the variance of individual η(1). CV% is the coefficient of variance and represents interindividual variability in the population. CV% = sqrt {[exp (variance)]−1}